Dicerna Pharmaceuticals (NASDAQ: DRNA) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Dicerna Pharmaceuticals to similar companies based on the strength of its analyst recommendations, dividends, profitability, risk, institutional ownership, earnings and valuation.

Insider and Institutional Ownership

54.4% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 29.4% of Dicerna Pharmaceuticals shares are owned by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Dicerna Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Dicerna Pharmaceuticals $290,000.00 -$59.51 million -2.21
Dicerna Pharmaceuticals Competitors $284.49 million $33.78 million 75.79

Dicerna Pharmaceuticals’ peers have higher revenue and earnings than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Dicerna Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dicerna Pharmaceuticals -5,895.26% -293.25% -87.25%
Dicerna Pharmaceuticals Competitors -5,993.97% -219.09% -39.48%

Analyst Ratings

This is a summary of recent recommendations for Dicerna Pharmaceuticals and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dicerna Pharmaceuticals 0 1 3 0 2.75
Dicerna Pharmaceuticals Competitors 866 3223 11693 232 2.71

Dicerna Pharmaceuticals currently has a consensus price target of $7.00, indicating a potential downside of 7.83%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 47.35%. Given Dicerna Pharmaceuticals’ peers higher probable upside, analysts clearly believe Dicerna Pharmaceuticals has less favorable growth aspects than its peers.

Volatility & Risk

Dicerna Pharmaceuticals has a beta of 2.84, indicating that its share price is 184% more volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals’ peers have a beta of 8.49, indicating that their average share price is 749% more volatile than the S&P 500.

Summary

Dicerna Pharmaceuticals peers beat Dicerna Pharmaceuticals on 7 of the 12 factors compared.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).

Receive News & Stock Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related stocks with our FREE daily email newsletter.